FAST NEWS: Fosun Pharma’s Revenue Growth Slows Sharply in Third Quarter
The latest: Shanghai Fosun Pharmaceutical (Group) Co. Ltd. (2196.HK; 600196.SH) said Sunday its revenue increased 1.7% year-on-year to 10.27 billion yuan ($1.4 billion) in the third quarter, as measured using…
RELATED ARTICLES
-
Fosun moves on from debt crisis with renewed focus on tourism, healthcare
0656.HK -
Fosun Tourism travels back to home base with delisting plan
1992.HK 0656.HK
-
BRIEF: Fosun pledges 27% of Fosun Pharma’s A-shares
2196.HK 600196.SHG
-
After a failed Fosun buyout, what’s next for drug maker Henlius Biotech?
2696.HK
-
NaaS drives into third quarter with first-ever quarterly non-IFRS profit
NAAS.US
-
Bumper dividend could trigger buyout for Ping An Health
1833.HK
- TCMTech fuses old with the new by mixing AI and Chinese medicine
